Novartis announced that the European Commission has approved Bexsero (Meningococcal Group B Vaccine [rDNA, component, adsorbed]) for use in individuals from 2 months of age and older. Following this approval, EU member states will evaluate Bexsero for potential inclusion into national immunization programs and, where relevant, reimbursement schemes. Novartis said it is already engaging with governments interested in the early adoption of the vaccine. Full media release:

http://www.novartis.com/newsroom/media-releases/en/2013/1672036.shtml